Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.38
STJ's Cash to Debt is ranked lower than
52% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. STJ: 0.38 )
STJ' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 0.38

Equity to Asset 0.41
STJ's Equity to Asset is ranked lower than
52% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. STJ: 0.41 )
STJ' s 10-Year Equity to Asset Range
Min: 0.41   Max: 0.81
Current: 0.41

0.41
0.81
Interest Coverage 12.98
STJ's Interest Coverage is ranked higher than
52% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 205.72 vs. STJ: 12.98 )
STJ' s 10-Year Interest Coverage Range
Min: 7.08   Max: 9999.99
Current: 12.98

7.08
9999.99
F-Score: 5
Z-Score: 3.34
M-Score: -2.44
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 19.11
STJ's Operating margin (%) is ranked higher than
90% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. STJ: 19.11 )
STJ' s 10-Year Operating margin (%) Range
Min: 13.95   Max: 38.93
Current: 19.11

13.95
38.93
Net-margin (%) 13.14
STJ's Net-margin (%) is ranked higher than
87% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. STJ: 13.14 )
STJ' s 10-Year Net-margin (%) Range
Min: 2.17   Max: 22.02
Current: 13.14

2.17
22.02
ROE (%) 17.09
STJ's ROE (%) is ranked higher than
93% of the 365 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. STJ: 17.09 )
STJ' s 10-Year ROE (%) Range
Min: 3.05   Max: 23.39
Current: 17.09

3.05
23.39
ROA (%) 7.06
STJ's ROA (%) is ranked higher than
83% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. STJ: 7.06 )
STJ' s 10-Year ROA (%) Range
Min: 1.56   Max: 14.16
Current: 7.06

1.56
14.16
ROC (Joel Greenblatt) (%) 39.98
STJ's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 12.55 vs. STJ: 39.98 )
STJ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 18.34   Max: 59.77
Current: 39.98

18.34
59.77
Revenue Growth (%) 6.60
STJ's Revenue Growth (%) is ranked higher than
75% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. STJ: 6.60 )
STJ' s 10-Year Revenue Growth (%) Range
Min: -6.7   Max: 28.9
Current: 6.6

-6.7
28.9
EBITDA Growth (%) -4.60
STJ's EBITDA Growth (%) is ranked higher than
73% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. STJ: -4.60 )
STJ' s 10-Year EBITDA Growth (%) Range
Min: -4.6   Max: 22.2
Current: -4.6

-4.6
22.2
EPS Growth (%) -3.30
STJ's EPS Growth (%) is ranked higher than
73% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. STJ: -3.30 )
STJ' s 10-Year EPS Growth (%) Range
Min: -37   Max: 120.5
Current: -3.3

-37
120.5
» STJ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

STJ Guru Trades in Q1 2013

Ken Fisher 308,620 sh (+58.51%)
James Barrow 2,735,000 sh (+41.47%)
Steven Cohen 5,489 sh (+37.43%)
John Rogers 1,675,741 sh (+24.17%)
Joel Greenblatt 90,730 sh (+24.08%)
Mario Gabelli 81,106 sh (+16.41%)
Bill Frels 1,915,010 sh (+1.51%)
Jeremy Grantham 236,563 sh (+0.3%)
Paul Tudor Jones Sold Out
David Dreman 139,110 sh (-3.81%)
Ray Dalio 340,949 sh (-18.52%)
Sarah Ketterer 425,000 sh (-24.48%)
Vanguard Health Care Fund 7,500,400 sh (-25.82%)
John Hussman 4,900 sh (-99.53%)
» More
Q2 2013

STJ Guru Trades in Q2 2013

John Buckingham 106,386 sh (New)
Pioneer Investments 4,676 sh (New)
Jim Simons 316,813 sh (New)
Steven Cohen 19,738 sh (+259.59%)
John Rogers 1,795,866 sh (+7.17%)
Mario Gabelli 85,010 sh (+4.81%)
James Barrow 2,815,600 sh (+2.95%)
Bill Frels 1,944,947 sh (+1.56%)
John Hussman 4,900 sh (unchged)
Sarah Ketterer Sold Out
Ken Fisher 304,013 sh (-1.49%)
Vanguard Health Care Fund 7,237,300 sh (-3.51%)
Jeremy Grantham 223,863 sh (-5.37%)
David Dreman 131,373 sh (-5.56%)
Joel Greenblatt 54,280 sh (-40.17%)
Ray Dalio 105,185 sh (-69.15%)
» More
Q3 2013

STJ Guru Trades in Q3 2013

Paul Tudor Jones 4,200 sh (New)
Steven Cohen 273,744 sh (+1286.89%)
Bill Frels 2,119,012 sh (+8.95%)
James Barrow 3,062,827 sh (+8.78%)
Ken Fisher 309,565 sh (+1.83%)
John Buckingham 106,684 sh (+0.28%)
Steven Cohen 300,000 sh (unchged)
Pioneer Investments Sold Out
John Hussman Sold Out
Ray Dalio Sold Out
Jim Simons Sold Out
Jeremy Grantham 207,433 sh (-7.34%)
Mario Gabelli 74,618 sh (-12.22%)
John Rogers 1,573,176 sh (-12.4%)
Vanguard Health Care Fund 6,297,900 sh (-12.98%)
Joel Greenblatt 27,075 sh (-50.12%)
David Dreman 49,625 sh (-62.23%)
» More
Q4 2013

STJ Guru Trades in Q4 2013

Andreas Halvorsen 1,486,735 sh (New)
John Hussman 350,000 sh (New)
Paul Tudor Jones 11,101 sh (+164.31%)
Jeremy Grantham 224,404 sh (+8.18%)
John Buckingham 110,152 sh (+3.25%)
James Barrow 3,151,847 sh (+2.91%)
John Rogers 1,604,471 sh (+1.99%)
Vanguard Health Care Fund 6,297,900 sh (unchged)
Bill Frels 2,110,787 sh (-0.39%)
Mario Gabelli 73,189 sh (-1.92%)
Ken Fisher 267,380 sh (-13.63%)
Joel Greenblatt 17,326 sh (-36.01%)
David Dreman 27,489 sh (-44.61%)
Steven Cohen 19,952 sh (-92.71%)
» More
» Details

Insider Trades

Latest Guru Trades with STJ

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-12-31 New Buy1.5%$54.58 - $62.74 $ 62.498%350000
David Dreman 2013-12-31 Reduce -44.61%0.11%$54.58 - $62.74 $ 62.498%27489
Joel Greenblatt 2013-12-31 Reduce -36.01%0.02%$54.58 - $62.74 $ 62.498%17326
Vanguard Health Care Fund 2013-09-30 Reduce -12.98%0.16%$45.6 - $54.03 $ 62.4921%6297900
David Dreman 2013-09-30 Reduce -62.23%0.12%$45.6 - $54.03 $ 62.4921%49625
Joel Greenblatt 2013-09-30 Reduce -50.12%0.06%$45.6 - $54.03 $ 62.4921%27075
Ray Dalio 2013-09-30 Sold Out 0.04%$45.6 - $54.03 $ 62.4921%0
John Hussman 2013-09-30 Sold Out 0.01%$45.6 - $54.03 $ 62.4921%0
Ray Dalio 2013-06-30 Reduce -69.15%0.09%$39.95 - $47 $ 62.4944%105185
Joel Greenblatt 2013-06-30 Reduce -40.17%0.08%$39.95 - $47 $ 62.4944%54280
John Hussman 2013-03-31 Reduce -99.53%0.99%$36.14 - $43.12 $ 62.4954%4900
Vanguard Health Care Fund 2013-03-31 Reduce -25.82%0.25%$36.14 - $43.12 $ 62.4954%7500400
James Barrow 2013-03-31 Add 41.47%0.06%$36.14 - $43.12 $ 62.4954%2735000
Joel Greenblatt 2013-03-31 Add 24.08%0.04%$36.14 - $43.12 $ 62.4954%90730
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about St Jude Medical, Inc.

Weekly 52-Week Highs Highlight: PPG, STJ, V, LLTC, LUV
According to GuruFocus list of 52-week highs, PPG Industries Inc., St Jude Medical Inc., Visa Inc., Linear Technology and Southwest Airlines Co. have all recently reached their 52-week highs. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 24.90
STJ's P/E(ttm) is ranked higher than
69% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 26.70 vs. STJ: 24.90 )
STJ' s 10-Year P/E(ttm) Range
Min: 12.71   Max: 51.32
Current: 24.9

12.71
51.32
P/B 4.40
STJ's P/B is ranked lower than
55% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. STJ: 4.40 )
STJ' s 10-Year P/B Range
Min: 2.13   Max: 8.2
Current: 4.4

2.13
8.2
P/S 3.30
STJ's P/S is ranked lower than
53% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. STJ: 3.30 )
STJ' s 10-Year P/S Range
Min: 1.84   Max: 7.3
Current: 3.3

1.84
7.3
PFCF 24.60
STJ's PFCF is ranked higher than
65% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 27.48 vs. STJ: 24.60 )
STJ' s 10-Year PFCF Range
Min: 9.89   Max: 41.61
Current: 24.6

9.89
41.61
EV-to-EBIT 18.90
STJ's EV-to-EBIT is ranked higher than
66% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 20.91 vs. STJ: 18.90 )
STJ' s 10-Year EV-to-EBIT Range
Min: 10   Max: 34.3
Current: 18.9

10
34.3
PEG 83.70
STJ's PEG is ranked lower than
70% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. STJ: 83.70 )
STJ' s 10-Year PEG Range
Min: 0.72   Max: 84.5
Current: 83.7

0.72
84.5
Shiller P/E 26.50
STJ's Shiller P/E is ranked higher than
64% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 27.00 vs. STJ: 26.50 )
STJ' s 10-Year Shiller P/E Range
Min: 14.43   Max: 74.61
Current: 26.5

14.43
74.61

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.60
STJ's Dividend Yield is ranked higher than
67% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.28 vs. STJ: 1.60 )
STJ' s 10-Year Dividend Yield Range
Min: 0.39   Max: 2.81
Current: 1.6

0.39
2.81
Dividend Payout 0.40
STJ's Dividend Payout is ranked higher than
56% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 0.35 vs. STJ: 0.40 )
STJ' s 10-Year Dividend Payout Range
Min: 0.18   Max: 0.4
Current: 0.4

0.18
0.4
Yield on cost (5-Year) 1.60
STJ's Yield on cost (5-Year) is ranked higher than
61% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 1.39 vs. STJ: 1.60 )
STJ' s 10-Year Yield on cost (5-Year) Range
Min: 0.39   Max: 2.81
Current: 1.6

0.39
2.81
Share Buyback Rate 4.20
STJ's Share Buyback Rate is ranked higher than
97% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: -1.30 vs. STJ: 4.20 )
STJ' s 10-Year Share Buyback Rate Range
Min: 4.2   Max: -16.1
Current: 4.2

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.50
STJ's Price/DCF (Projected) is ranked higher than
72% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. STJ: 1.50 )
STJ' s 10-Year Price/DCF (Projected) Range
Min: 0.89   Max: 5.51
Current: 1.5

0.89
5.51
Price/Median PS Value 1.00
STJ's Price/Median PS Value is ranked higher than
66% of the 338 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. STJ: 1.00 )
STJ' s 10-Year Price/Median PS Value Range
Min: 0.58   Max: 1.95
Current: 1

0.58
1.95
Price/Peter Lynch Fair Value 3.20
STJ's Price/Peter Lynch Fair Value is ranked lower than
58% of the 59 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. STJ: 3.20 )
STJ' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.94   Max: 20.74
Current: 3.2

0.94
20.74
Earnings Yield (Greenblatt) 5.30
STJ's Earnings Yield (Greenblatt) is ranked higher than
72% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. STJ: 5.30 )
STJ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.9   Max: 10
Current: 5.3

2.9
10
Forward Rate of Return (Yacktman) 11.15
STJ's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. STJ: 11.15 )
STJ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 11.5   Max: 24.4
Current: 11.15

11.5
24.4

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, EW » details
Traded in other countries:JUD.Germany
St. Jude Medical, Inc. was incorporated in Minnesota in 1976. The Company develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiology and cardiac surgery and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. The Company's four operating segments are Cardiac Rhythm Management (CRM), Cardiovascular (CV), Atrial Fibrillation (AF) and Neuromodulation (NMD). Cardiac Rhythm Management engages in research, development and manufacture of products for cardiac arrhythmias, or irregular heartbeats. Its main products are tachycardia implantable cardioverter defibrillator systems (ICDs) and bradycardia pacemaker systems (pacemakers). The Cardiovascular division participates in segments of the vascular and structural heart markets. The main products of Cardiovascular are vascular products, which include vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs and other vascular accessories, and structural heart products, which include heart valve replacement and repair products and structural heart defect devices; Atrial Fibrillation is a condition in which the upper chambers of the heart (atria) beat rapidly and erratically, affecting the heart's ability to adequately pump blood to its lower chambers (ventricles) and subsequently to the rest of the body. Some of the complications caused by AF are increased risk of death or stroke, increased severity of stroke, increased hospitalizations, and reduced quality of life due to palpitations and other AF-related symptoms. Its products include electrophysiology (EP) introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems. Neuromodulation product offerings provide neurostimulation treatment in which an implantable device delivers electrical current directly to targeted nerve sites. Its products are neurostimulation, which include spinal cord and deep brain stimulation devices. The Company markets and sells its products through both a direct sales force and independent distributors. The main geographic markets for its products are the United States, Europe, Japan and Asia Pacific. The Company's main competitors in this market are Medtronic, Inc. and Boston Scientific Corporation. These two competitors have invested substantial amounts in CRM research and development in a highly competitive market where rapid technological change is expected to continue, requiring the Company to invest heavily in R&D and effectively market its products. The Company's products, development activities and manufacturing processes are subject to extensive and rigorous regulation by the FDA pursuant to the Federal Food, Drug, and Cosmetic Act (FDCA), by comparable agencies in foreign countries and by other regulatory agencies and governing bodies.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide